Pomalidomide

Generic Name: Pomalidomide

Brand Names: Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₁N_₃O_₄

CAS Number: 19171-19-8

Unique Ingredient Identifier: D2UX06XLB5

Background: Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.

Indication: Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...

Associated Conditions: Kaposi's Sarcoma, Multiple Myeloma (MM)

Associated Therapies: -

Clinical Trials

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2011-12-22

Last Posted Date: 2020-04-07

Lead Sponsor: Celgene

Target Recruit Count: 34

Registration Number: NCT01497093

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 3 locations

Pomalidomide for Kaposi Sarcoma in People With or Without HIV

Phase 1

Completed

Conditions: Kaposi Sarcoma
Sarcoma, Kaposi

Interventions: Drug: Pomalidomide

First Posted Date: 2011-12-20

Last Posted Date: 2022-11-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT01495598

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pomalidomide
Drug: Placebo

First Posted Date: 2011-11-18

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 33

Registration Number: NCT01474330

Locations: 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2011-11-03

Last Posted Date: 2022-08-01

Lead Sponsor: Criterium, Inc.

Target Recruit Count: 136

Registration Number: NCT01464034

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
The John Theurer Cancer Center @ Hackensack UMC, Hackensack, New Jersey, United States

and more 6 locations

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Phase 1

Completed

Conditions: Myeloma

Interventions: Drug: Pomalidomide
Drug: Dexamethasone
Drug: Cyclophosphamide

First Posted Date: 2011-09-13

Last Posted Date: 2017-05-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 80

Registration Number: NCT01432600

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Mount Sinai School of Medicine, The Tisch Cancer Institute, New York, New York, United States

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: MOR03087 phase 1 dose escalation
Drug: MOR03087
Drug: Dexamethasone
Drug: Pomalidomide
Drug: Lenalidomide

First Posted Date: 2011-08-22

Last Posted Date: 2021-11-16

Lead Sponsor: MorphoSys AG

Target Recruit Count: 91

Registration Number: NCT01421186

Locations: 🇦🇹
AKH (Allgemeines Krankenhaus der Stadt Wien), Abteilung für Klinische Onkologie, Universitätsklinik für Innere Medizin I, Vienna, Austria
🇩🇪
Medizinische Klinik II, Abt. Hämatologie, Onkologie,, Tübingen, Germany
🇩🇪
Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Studienambulanz für Hämatologie/Onkologie und Infektiologie, Würzburg, Germany

and more 7 locations

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: pomalidomide

First Posted Date: 2011-03-29

Last Posted Date: 2019-11-19

Lead Sponsor: Celgene

Target Recruit Count: 74

Registration Number: NCT01324947

Locations: 🇪🇸
Hospital de Donostia - Hematology, Guipúzcoa, Spain
🇨🇦
Royal Victoria Hospital, Montreal, Quebec, Canada
🇦🇺
Border Medical Oncology, Wodonga, Australia

and more 88 locations

Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide

First Posted Date: 2011-03-21

Last Posted Date: 2016-08-11

Lead Sponsor: Yale University

Target Recruit Count: 40

Registration Number: NCT01319422

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: pomalidomide

First Posted Date: 2011-03-09

Last Posted Date: 2018-10-24

Lead Sponsor: Celgene

Target Recruit Count: 455

Registration Number: NCT01311687

Locations: 🇧🇪
CHU UCL Mont-Godinne-Dinant asbl, Yvoir, Belgium
🇷🇺
St. Petersburg Research Institute of Hematology and Blood Transfusion, St. Petersburg, Russian Federation
🇷🇺
State Institution Moscow Regional Research Clinical Institute, Moscow, Russian Federation

and more 91 locations

Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma

Interventions: Drug: pomalidomide
Drug: bortezomib
Drug: dexamethasone
Other: laboratory biomarker analysis
Other: gene expression analysis

First Posted Date: 2010-10-01

Last Posted Date: 2020-04-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 50

Registration Number: NCT01212952

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy